Valuation: Virbac

Market Cap 2.89B 3.3B 2.7B 2.48B 4.65B 315B 4.73B 31.98B 12.52B 156B 12.38B 12.11B 540B P/E 2026 *
17x
P/E 2027 * 15.3x
Enterprise Value 3.02B 3.44B 2.81B 2.59B 4.85B 329B 4.93B 33.38B 13.06B 163B 12.92B 12.65B 564B EV / Sales 2026 *
1.95x
EV / Sales 2027 * 1.8x
Free-Float
49.03%
Yield 2026 *
0.5%
Yield 2027 * 0.59%
1 day-6.07%
1 week-6.07%
Current month-6.07%
1 month-6.07%
3 months-0.39%
6 months-12.16%
Current year-12.16%
1 month 382.75
Extreme 382.75
413.75
Current year 382.75
Extreme 382.75
413.75
1 year 382.75
Extreme 382.75
436.32
3 years 288
Extreme 288
436.32
5 years 288
Extreme 288
436.32
10 years 131
Extreme 131
436.32
Manager TitleAgeSince
Chief Executive Officer 46 01/09/2025
Chief Executive Officer 50 27/09/2024
Chief Operating Officer 64 01/01/2022
Director TitleAgeSince
Chairman 61 01/04/2006
Director/Board Member 68 28/07/2010
Director/Board Member 65 05/09/2017
Change 5-day change 1-year change 3-year change Capi.($)
-6.07%-6.07% - - 3.3B
+0.77%+2.87%-48.58%-59.18% 32.49B
+0.43%+0.16%+75.03%+112.84% 12.75B
+0.74%+2.89%-18.25%0.00% 3.73B
-1.28%+3.09%+2.07%+28.48% 1.92B
-0.36%-3.21%+24.61%+10.08% 1.8B
+3.21%+7.41%+25.76%+153.10% 1.47B
-0.38%-3.02%-27.62%-16.83% 1.05B
-0.27%+1.26%-7.75%-21.34% 964M
+0.95%-0.31%-18.88%-47.88% 966M
Average -0.29%+1.47%+0.71%+17.70% 6.35B
Weighted average by Cap. +0.23%+1.97%-11.53%-4.74%

Financials

2026 *2027 *
Net sales 1.55B 1.77B 1.44B 1.33B 2.49B 169B 2.53B 17.12B 6.7B 83.67B 6.63B 6.49B 289B 1.65B 1.88B 1.53B 1.41B 2.64B 179B 2.69B 18.19B 7.12B 88.89B 7.04B 6.89B 307B
Net income 171M 195M 159M 147M 275M 18.63B 279M 1.89B 740M 9.24B 732M 716M 31.92B 190M 216M 177M 163M 305M 20.68B 310M 2.1B 821M 10.25B 813M 795M 35.43B
Net Debt 127M 144M 118M 109M 203M 13.8B 207M 1.4B 548M 6.84B 542M 530M 23.64B 75.16M 85.64M 69.99M 64.37M 121M 8.18B 123M 830M 325M 4.06B 322M 315M 14.02B
Logo Virbac
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
6,442
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
345.50EUR
Average target price
412.00EUR
Spread / Average Target
+19.25%

Quarterly revenue - Rate of surprise